Merck & Co (NY:MRK)

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

Topics Artificial Intelligence Supply Chain

March 03, 2026

To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

Topics Earnings Supply Chain

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier

Topics Artificial Intelligence

March 02, 2026

The United States Department of Agriculture (USDA) has officially greenlit a massive $100 million initiative dubbed the "Screwworm Challenge," aimed at neutralizing a resurgent biological threat that...

Merck & Co. Inc. (NYSE:MRK) Emerges as a Strong Dividend Contender Through Methodical Screening ↗

Topics Economy

February 19, 2026

Via Chartmill

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

Topics Artificial Intelligence

February 28, 2026

From Merck & Co., Inc

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 28, 2026

The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark...

Topics Lawsuit

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

Topics Artificial Intelligence Economy Electric Vehicles

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

February 27, 2026

The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While...

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Topics Artificial Intelligence Economy

February 27, 2026

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

February 27, 2026

Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results

February 26, 2026

Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir...

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

Topics Intellectual Property

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

Topics Economy Intellectual Property

February 26, 2026

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...

Via Finterra

Topics Earnings Economy Intellectual Property

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,...

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

Topics Intellectual Property

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

Topics Intellectual Property

February 25, 2026

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

February 25, 2026

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

February 24, 2026

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

February 23, 2026

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

The company might bend, but it won't break.

Topics Intellectual Property

Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades ↗

February 22, 2026

Merck has an attractive yield and a long history of dividend growth.

Topics Intellectual Property

Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement? ↗

February 22, 2026

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

Topics Intellectual Property

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

Topics Lawsuit

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

February 19, 2026

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

February 18, 2026

From Merck & Co., Inc. and Mayo Clinic